DeLong Mark Jeffrey

CIK 00018560781 companyWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001856078

Recent Transactions

50 trades

Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−14,799→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−24,666→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−30,845→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−6,952→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−30,000→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−18,750→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−27,224→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−82,500→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−21,381→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−8,482→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−4,909→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−36,606→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−18,303→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+18,303→ 18,303 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−36,606→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+36,606→ 36,606 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−19,006→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+19,006→ 19,006 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−41,250→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+41,250→ 41,250 total
Disposition from Tender
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−114,591→ 0 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-02-11$22.15/sh−368→ 114,591 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-28+36,606→ 114,959 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-22$21.77/sh−3,371→ 78,353 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-20$19.79/sh−1,334→ 81,724 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-06-09$19.39/sh+82,500→ 82,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-02-11$28.54/sh−363→ 83,945 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-29$29.52/sh−365→ 84,308 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-22$30.43/sh−1,396→ 84,673 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-21+28,508→ 86,069 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-17$29.96/sh−1,235→ 57,561 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-13$28.70/sh−1,599→ 58,796 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-08-12$13.85/sh+5,201→ 60,395 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-08-12−5,201→ 14,799 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-18$56.90/sh−9,913→ 54,693 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-02-12$67.77/sh−597→ 64,606 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-29$64.14/sh−367→ 65,203 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-22$65.00/sh−1,384→ 65,570 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-01-16$66.30/sh+24,666→ 24,666 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16+16,963→ 68,585 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16$66.81/sh−1,631→ 66,954 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-10-23$46.04/sh−131→ 51,622 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-21$58.50/sh−441→ 51,341 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-02-21+7,489→ 7,489 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-21+5,280→ 51,782 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-10$51.21/sh−670→ 46,502 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-27$52.77/sh−367→ 47,172 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-20$52.05/sh−1,149→ 47,539 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-12+19,634→ 48,688 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-01-12$52.66/sh+30,845→ 30,845 total

Companies

Apellis Pharmaceuticals, Inc.
Chief Business & Strat Officer
$APLS

Recent Filings

4
DeLong Mark Jeffrey
May 14, 2026

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451

View on SEC.gov